Novo Nordisk cancels further development of vatreptacog alfa as a treatment for Diabetes

Novo Nordisk has announced the decision to discontinue the development of vatreptacog alfa, a fast-acting recombinant factor VIIa analogue for haemophilia patients with inhibitors. The decision follows analysis of the data from the phase IIIa trial adeptTM 2. A few patients in the trial had developed anti-drug antibodies to vatreptacog alfa, one patient with a potentially neutralising effect.